SELLAS Life Sciences (SLS) EBITDA (2010 - 2026)
SELLAS Life Sciences (SLS) reported EBITDA of -$9.3 million for Q1 2026, down 52.6% year-over-year from -$19.5 million in Q1 2025, and down 12.08% quarter-over-quarter from -$8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) EBITDA (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 15 years of EBITDA data on file, last reported at -$9.3 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$9.3 million, down 52.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.5 million (down 12.65% YoY), and the FY2025 annual result was -$28.3 million, up 10.28% from the prior year.
- EBITDA eased to -$9.3 million in Q1 2026 per SLS's latest filing, from -$8.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$6.1 million in Q1 2025 and troughed at -$16.7 million in Q1 2022.
- A 5-year average of -$8.8 million and a median of -$8.3 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 645.43% in 2022, then surged 37.14% in 2025.
- A 5-year view of EBITDA shows it stood at -$9.4 million in 2022, then increased by 13.43% to -$8.2 million in 2023, then gained by 15.4% to -$6.9 million in 2024, then decreased by 19.33% to -$8.3 million in 2025, then dropped by 12.08% to -$9.3 million in 2026.
- Business Quant data shows SLS's EBITDA at -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -9.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -6.06 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -7.33 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |